Arvest Bank Trust Division Has $1.38 Million Stake in Pfizer Inc. $PFE

Arvest Bank Trust Division reduced its position in Pfizer Inc. (NYSE:PFE) by 22.7% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,719 shares of the biopharmaceutical company’s stock after selling 16,695 shares during the period. Arvest Bank Trust Division’s holdings in Pfizer were worth $1,375,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Vanguard Group Inc. increased its position in shares of Pfizer by 0.9% during the first quarter. Vanguard Group Inc. now owns 523,165,127 shares of the biopharmaceutical company’s stock worth $13,257,004,000 after acquiring an additional 4,629,976 shares in the last quarter. Geode Capital Management LLC boosted its stake in Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock valued at $3,080,552,000 after purchasing an additional 1,820,634 shares during the last quarter. Northern Trust Corp increased its holdings in Pfizer by 6.8% during the 1st quarter. Northern Trust Corp now owns 62,325,957 shares of the biopharmaceutical company’s stock worth $1,579,340,000 after purchasing an additional 3,943,397 shares in the last quarter. Amundi raised its stake in shares of Pfizer by 43.4% in the first quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company’s stock worth $1,265,277,000 after purchasing an additional 15,758,846 shares during the last quarter. Finally, Invesco Ltd. lifted its holdings in shares of Pfizer by 2.8% in the first quarter. Invesco Ltd. now owns 30,296,337 shares of the biopharmaceutical company’s stock valued at $767,709,000 after purchasing an additional 838,198 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on PFE. Citigroup upped their price target on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a report on Wednesday, August 6th. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a report on Friday, October 31st. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 price target on shares of Pfizer in a report on Wednesday, November 5th. UBS Group reiterated a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Finally, Scotiabank assumed coverage on Pfizer in a research note on Thursday. They issued a “sector outperform” rating and a $30.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $28.28.

Pfizer Trading Down 0.3%

Shares of PFE stock opened at $25.80 on Friday. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The firm has a market cap of $146.66 billion, a P/E ratio of 13.72, a PEG ratio of 0.81 and a beta of 0.54. The company has a 50 day moving average of $24.79 and a 200-day moving average of $24.43. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $27.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 7th will be paid a dividend of $0.43 per share. The ex-dividend date is Friday, November 7th. This represents a $1.72 annualized dividend and a dividend yield of 6.7%. Pfizer’s dividend payout ratio is presently 100.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.